Mr. Cable represents as outside general counsel to a number of private and public companies, where he counsels boards of directors and management teams on corporate governance, mergers and acquisitions, and disclosure and securities law matters. His recent M&A transactions include the sale of Onyx Pharmaceuticals to Amgen ($10.4 billion), the sale of Eloqua to Oracle ($1 billion), the majority sale of Foundation Medicine to Roche ($1 billion), the sale of Idenix to Merck ($3.8 billion), the sale of Pharmacyclics to AbbVie ($21 billion), the sale of Xoom to PayPal ($1 billion), the acquisition of Auspex by Teva Pharmaceuticals ($3.5 billion) and the acquisition of Cord Blood Registry by AMAG Pharmaceuticals ($700 million). In the course of his career, Mr. Cable has negotiated and executed over 300 M&A transactions. Mr. Cable also serves regularly as counsel to issuers in IPOs, follow-on offerings and convertible debt transactions, and acts regularly as counsel for the underwriters in such transactions.
Stuart M. Cable
Stuart Cable represents as outside general counsel public and private companies involved in the life sciences and technology sector. Mr. Cable also represents private equity and venture sources investing in such companies and investment banks serving such industries. He currently serves as Goodwin’s chair of M&A/Corporate Finance for its Technology and Life Sciences business practices. He previously served as chair of the firm's Corporate Department, as chair of its Hiring Committee, as chair of its Incubator, and as a member of its Executive and Allocations Committees.
Mr. Cable serves as a member of the President's Leadership Council at Dartmouth College and as chairman emeritus of the Buckingham Browne & Nichols School. He also serves as a member of the Board of Fellows of Harvard Medical School.
Mr. Cable is annually ranked in Chambers USA: America’s Leading Lawyers for Business (Corporate/M&A – Band 1), Chambers Global: The Leading Lawyers for Business (Corporate/M&A) and U.S. News-Best Lawyers (Corporate Law). Global M&A Network has named him one of the world’s top 50 M&A lawyers, recognizing his work advising Onyx Pharmaceuticals in its $10.4 billion purchase by Amgen – a transaction named 2014 Global Major Markets Life Sciences Deal of the Year. He has also been recognized in The Legal 500 U.S. for his M&A work.
U.S. News - Best Lawyers®Biotechnology Law Firm of the Year
Columbia Law School
(Harlan Fiske Stone Scholar)
Tuck School of Business at Dartmouth
(magna cum laude)